OncoMatch/Clinical Trials/NCT06371586
Neo-Sequence 2：NCT Plus Anti-angiogenesis Therapy and Immunotherapy for LADGC
Is NCT06371586 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Albumin paclitaxel+SOX+BEV+ PD-1 monoclonal antibody therapy for gastric cancer.
Treatment: Albumin paclitaxel+SOX+BEV+ PD-1 monoclonal antibody therapy — The regimen of Albumin paclitaxel+SOX+BEV neoadjuvant therapy lasted for 6 cycles, during which PD-1 monoclonal antibody therapy was interspersed for 4 cycles for locally advanced diffuse gastric cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Cancer type
Gastric Cancer
Disease stage
Required: Stage T3-4NANYM0 (AJCC 8th edition)
T3-4NanyM0 gastric cancer or gastroesophageal junction cancer (refer to AJCC staging, 8th edition)
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Lab requirements
Blood counts
Neutrophils >1.5G/L, Hb >90g/L, PLT >100G/L
Kidney function
Cr <1.0ULN
Liver function
ALT and AST <2.5ULN; TBIL <1.5 ULN
Cardiac function
Left ventricular ejection fraction >60%
Neutrophils>1.5G/L, Hb>90g/L, PLT>100G/L; ALT and AST<2.5ULN; TBIL<1.5 ULN; Cr<1.0ULN; Left ventricular ejection fraction>60%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06371586 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage T3-4NANYM0 is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages